Found: 15
Select item for more details and to access through your institution.
Combination of denosumab and immune checkpoint inhibition: experience in 29 patients with metastatic melanoma and bone metastases.
- Published in:
- Cancer Immunology, Immunotherapy, 2019, v. 68, n. 7, p. 1187, doi. 10.1007/s00262-019-02353-5
- By:
- Publication type:
- Article
Comparison of IL-2 vs IL-7/IL-15 for the generation of NY-ESO-1-specific T cells.
- Published in:
- Cancer Immunology, Immunotherapy, 2019, v. 68, n. 7, p. 1195, doi. 10.1007/s00262-019-02354-4
- By:
- Publication type:
- Article
Pembrolizumab as first-line treatment for metastatic uveal melanoma.
- Published in:
- Cancer Immunology, Immunotherapy, 2019, v. 68, n. 7, p. 1179, doi. 10.1007/s00262-019-02352-6
- By:
- Publication type:
- Article
Evaluation of the efficacy of immunotherapy for non-resectable mucosal melanoma.
- Published in:
- Cancer Immunology, Immunotherapy, 2019, v. 68, n. 7, p. 1171, doi. 10.1007/s00262-019-02351-7
- By:
- Publication type:
- Article
Patterns of immune-cell infiltration in murine models of melanoma: roles of antigen and tissue site in creating inflamed tumors.
- Published in:
- Cancer Immunology, Immunotherapy, 2019, v. 68, n. 7, p. 1121, doi. 10.1007/s00262-019-02345-5
- By:
- Publication type:
- Article
Clinicopathological implications of TIM3<sup>+</sup> tumor-infiltrating lymphocytes and the miR-455-5p/Galectin-9 axis in skull base chordoma patients.
- Published in:
- Cancer Immunology, Immunotherapy, 2019, v. 68, n. 7, p. 1157, doi. 10.1007/s00262-019-02349-1
- By:
- Publication type:
- Article
Impact of combination immunochemotherapies on progression of 4NQO-induced murine oral squamous cell carcinoma.
- Published in:
- Cancer Immunology, Immunotherapy, 2019, v. 68, n. 7, p. 1133, doi. 10.1007/s00262-019-02348-2
- By:
- Publication type:
- Article
Metabolic remodeling contributes towards an immune-suppressive phenotype in glioblastoma.
- Published in:
- Cancer Immunology, Immunotherapy, 2019, v. 68, n. 7, p. 1107, doi. 10.1007/s00262-019-02347-3
- By:
- Publication type:
- Article
First-in-human phase 1 dose-escalating trial of G305 in patients with advanced solid tumors expressing NY-ESO-1.
- Published in:
- Cancer Immunology, Immunotherapy, 2019, v. 68, n. 7, p. 1211, doi. 10.1007/s00262-019-02331-x
- By:
- Publication type:
- Article
PLAC1: biology and potential application in cancer immunotherapy.
- Published in:
- Cancer Immunology, Immunotherapy, 2019, v. 68, n. 7, p. 1039, doi. 10.1007/s00262-019-02350-8
- By:
- Publication type:
- Article
Novel circulating tumor cell-based blood test for the assessment of PD-L1 protein expression in treatment-naïve, newly diagnosed patients with non-small cell lung cancer.
- Published in:
- Cancer Immunology, Immunotherapy, 2019, v. 68, n. 7, p. 1087, doi. 10.1007/s00262-019-02344-6
- By:
- Publication type:
- Article
Inhibition of murine hepatoma tumor growth by cryptotanshinone involves TLR7-dependent activation of macrophages and induction of adaptive antitumor immune defenses.
- Published in:
- Cancer Immunology, Immunotherapy, 2019, v. 68, n. 7, p. 1073, doi. 10.1007/s00262-019-02338-4
- By:
- Publication type:
- Article
An HER2 DNA vaccine with evolution-selected amino acid substitutions reveals a fundamental principle for cancer vaccine formulation in HER2 transgenic mice.
- Published in:
- Cancer Immunology, Immunotherapy, 2019, v. 68, n. 7, p. 1143, doi. 10.1007/s00262-019-02333-9
- By:
- Publication type:
- Article
Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity.
- Published in:
- Cancer Immunology, Immunotherapy, 2019, v. 68, n. 7, p. 1095, doi. 10.1007/s00262-019-02346-4
- By:
- Publication type:
- Article
Cryptotanshinone has curative dual anti-proliferative and immunotherapeutic effects on mouse Lewis lung carcinoma.
- Published in:
- Cancer Immunology, Immunotherapy, 2019, v. 68, n. 7, p. 1059, doi. 10.1007/s00262-019-02326-8
- By:
- Publication type:
- Article